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ABSTRACT 
Introduction: Recent NICE guidance in England and Wales states that statin therapy for 
secondary CVD should “usually be initiated with a drug with a low acquisition cost (taking into 
account required daily dose and product price per dose)”. Intensive dose statin therapy is more 
costly than standard dose, but offers additional benefits and may potentially be more cost 
effective for a sub-group of high risk patients. 
 
Objective: To determine if the strategy of treating ACS patients with intensive dose statin 
compared with standard dose statin can be considered to be cost effective and to what extent these 
results are influenced by the age of the patient at start of treatment.   
 
Methods: A Markov model was used to explore the costs and health outcomes associated with a 
lifetime of intensive dose (represented by 80mg atorvastatin) versus standard dose (represented 
by 20mg simvastatin) treatment for patients with acute coronary syndrome.  Health states 
included unstable angina, MI, stroke, fatal CHD, fatal stroke, or non vascular death.  The benefits 
associated with statin treatment were modelled by applying the relative risks from a meta-analysis 
of 4 large RCTs reporting clinical endpoints.  Costs and utilities assigned to health states were 
derived from a review of published evidence.   
 
Results: Treatment with intensive dose statin therapy offers additional benefits over standard dose 
therapy.  The cost offsets through avoided events are less than the associated treatment costs and 
result in a cost per QALY of around £24,000 for patients with ACS starting treatment at 60 years 
of age and falling to around £14,000 for patients starting treatment at 70 years.  The key driver of 
cost effectiveness is the relative risk for mortality. 
 
Conclusions: This analysis suggests that intensive statin regimens (represented by atorvastatin 
80mg /day) are cost effective compared with standard statin regimens (represented by simvastatin 
20mg /day) for patients with ACS over the age of 60 years. A recent registry study report a mean 
age of 70 years for ACS patients admitted to UK hospitals and hence this comparison applies to 
the great majority of ACS patients.    
 
Key words: Statins; intensive dose therapy; cost effectiveness; acute coronary syndrome 
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INTRODUCTION 
 
Cardiovascular disease (CVD) remains one of the major causes of premature death in the United 
Kingdom, accounting for 35% of premature deaths in men and 27% in women. It is also a 
significant cause of morbidity. Statins have been shown to reduce the risk of cardiovascular 
events.1 Current NICE guidance in the UK recommends that patients with established coronary 
heart disease (CHD) should receive statins and statin therapy is also recommended as part of the 
management strategy for the primary prevention of CVD for adults who have a 20% or greater 
10-year risk of developing CVD.2 Over 5 million people, around 14% of adults in England, meet 
these eligibility criteria.  Statins currently account for 19 per cent of the total primary care drugs 
bill{2007 17952 /id} and this proportion is likely to grow as a result of more aggressive lipid 
lowering strategies resulting from the anticipated changes to both the GMS contract and the QOF, 
and a shift towards payment by result.4 Statin prescribing, at over £700 million per annum in 
2004, represented the largest drug cost to the NHS.5,6  Increasing adherence to guidelines over 
time will continue to put upward pressure on prescribing budgets. The relevance of cost effective 
prescribing of statins to the NHS is clear. 
 
Current NICE guidance states that “therapy should usually be initiated with a drug with a low 
acquisition cost (taking into account required daily dose and product price per dose)”.2 Five 
statins currently have a UK marketing authorisation: atorvastatin, fluvastatin, pravastatin, 
rosuvastatin and simvastatin, with simvastatin and atorvastatin currently dominating the UK 
market. Two of the five (simvastatin and pravastatin) have become available as generics, 
experiencing significant price reductions as a result. Perhaps not surprisingly, there has been a 
trend towards generic prescribing. It has been reported that switching from atorvastatin (10 to 
20mg /day) to simvastatin (20 to 40mg /day) saves around £1000 per patient over five years, 
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freeing up much needed resources for other uses.6 Figures reported by the Department of Health 
'Better Care, better value' indicators, indicate that the NHS could save at least £85m a year on 
drug acquisition costs through more efficient prescribing of statins.7 These savings are based on 
every PCT prescribing generic statins in 69 per cent of cases, the level achieved by the top quarter 
of Trusts. Importantly, this takes no account of the possible differences in individual patient and 
drug profiles and therefore the magnitude of  secondary costs following subsequent events. 
 
Recent draft guidance from NICE on lipid modification recommends that treatment for patients 
with established CVD “…should be initiated with simvastatin 40mg per day.”  Although they do 
not provide a target for total or LDL cholesterol it is recommended that “statins should be up-
titrate….. “statins should be up-titrated if the patient does not reach a total cholesterol of 4 
mmol/l or LDL cholesterol 2mmol/l on the initial dose.”2 This is in contrast to recent guidelines 
for management of patients with acute coronary syndrome issues by the European Society of 
Cardiology,8 American Heart Association and American College of Cardiology,9 which both 
advise that an optimal LDL cholesterol target of below 1.81 mmol/L (<70mg/dl) be adopted.  
These levels of cholesterol have only been achieved by a majority of patients in trials that have 
assessed intensive statin regimens, namely simvastatin or atorvastatin 80mg /day.   
 
Some Trusts in the UK have taken the decision to suspend prescribing of intensive dose statins, 
such as 40 – 80mg /day of atorvastatin, for patients with ACS and switch to prescribing of 40mg 
/day of simvastatin.10  Dose for dose, atorvastatin is more potent than simvastatin and an audit of 
the effect of this change in one hospital suggested that switching to the less efficacious statin may 
impact adversely on patient morbidity and mortality for this patient group.10  This audit raised 
questions about the level of additional benefit achieved by more intensive statin regimens and 
whether or not there is a group of high risk patients for whom the use of more intensive therapy 
for patients – in line with current clinical guidelines - is likely to be cost effective.  
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Four trials to date have presented clinical endpoint evidence for intensive versus standard dose 
statins on an intention-to-treat basis.11,12,13,14 The clinical setting and baseline risks of the 
populations varied - two trials were undertaken in patients after an acute coronary syndrome 
(ACS) event and two in populations with stable coronary artery disease (CAD). Three of the 
studies used 80 mg /day atorvastatin as the intensive statin regimen and one used a target dose of 
80 mg /day of simvastatin (A-to-Z). Standard statin regimens in these trials were simvastatin 
20mg /day,11,12 atorvastatin 10mg /day,13 and pravastatin 40 mg /day.14 Prescribing data for statins 
in England suggest that simvastatin 80mg /day is rarely used. (Prescription Cost Analysis 2005) 
 
In this paper we use this clinical evidence base to consider whether or not the strategy of treating 
ACS patients with intensive dose statin (represented by 80 mg /day atorvastatin) compared with 
standard dose statin (represented by 20mg /day simvastatin) can be considered to be cost effective 
and to what extent these results are influenced by the age of the patient at start of treatment.   
 
 
 
METHODS 
 
Model Design 
 
An existing Markov model constructed to evaluate the cost effectiveness of statin treatment 
versus no treatment was modified to compare intensive dose (80mg /day atorvastatin) with 
standard dose (20mg /day simvastatin) statin therapy for patients with existing cardiovascular 
disease.15  Markov models are particularly useful for cardiovascular interventions as the disease 
involves events that can occur more that once, a risk that increases over time and probabilities of 
subsequent events that change depending on the time since a previous event.16   
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The model replicates a hypothetical cohort moving between a finite number of mutually exclusive 
health states.  The current model consists of the following health states (Figure 1): new unstable 
angina, new MI, new stroke, post unstable angina, post MI, post stroke, fatal CHD, fatal stroke, or 
non vascular death.  Patients enter the model after experiencing a qualifying event: new unstable 
angina, new acute myocardial infarction or new non fatal stroke.  Patients move between health 
states annually until they have reached 100 years of age or die.  The transitions to subsequent 
events are higher in the first year after a new event than in subsequent years reflecting the 
increased risk during the initial period.  If an individual in a “new event” health state does not 
experience a subsequent event in the first year they move to the corresponding “post event” health 
state.  Markov models do not retain a memory of patients’ previous events thus transitions are 
conditional on current health state and age only.  Consequently we do not model transitions to 
health states with lower health state costs and higher quality of life (for example moving to 
unstable angina from stroke).  An exception is patients with a history of a stroke may experience 
an MI.  This is modelled using an additional health state (MI given stroke) where utilities, costs 
and future transitions are adjusted to reflect the history of stroke.  The proportion of patients in 
each of the health states is governed by age-dependent time-variant transition matrices which 
describe the annual probability of either moving to an alternative health state or remaining in the 
same health state.  Interim life tables adjusted for CV mortalities published by the UK 
Government Actuary Department were used to account for the proportion of patients dying from 
other causes. 
 
INSERT FIGURE 1: Patient pathway in Markov Model 
 
Event Rates 
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The baseline transition rates (Table 1) for patients who receive no treatment are taken from the 
statin HTA model.15  These are derived from logistic and multinomial regressions using patient 
level data from the South London Stroke Registry and the Nottingham Heart Attack Register.17,18 
 
INSERT TABLE 1: Examples of transitions for patients receiving no treatment15 
 
Effectiveness Rates 
The relative risks from a meta-analysis of placebo controlled statin RCTs are used to represent the 
effectiveness of standard statin therapy versus no treatment.  Of the 25 studies (n=35,721 for 
statin; n=35,432 for placebo) included in the meta-analyses used in the current evaluation, three 
of the four fluvastatin studies (FLARE, FLORIDA, LIPS) used the maximum dose of 80 mg /day 
while the LiSA study increased the starting dose of 40 mg /day to 80 mg /day 6 weeks after 
randomisation if the decrease in LDL-c was less than 30%.  Two of the four pravastatin studies 
used the maximum dose of 40 mg /day.  In the remaining two (PLAC II and PMSG), the dose 
could be increased to 40 mg /day in participants whose LDL-c levels had not responded to the 
starting dose of 20 mg /day.  Two of the six simvastatin studies (Aronow 2003, HPS) used 40 mg 
/day throughout while the MAAS study used a 20 mg /day dose throughout.  The remaining three 
(4S, CIS, SCAT) used a starting dose of 20 mg /day which could be increased to 40 mg /day if 
this was necessary to achieve an adequate reduction in LDL-c.   By contrast, the atorvastatin 
studies generally used doses well below the maximum dose of 80 mg /day: the ASCOT-LLA and 
CARDS studies used a fixed dose of 10 mg /day.  Only the small DALI (n=145 on atorvastatin) 
and Mohler (n=240 on atorvastatin) studies used an 80 mg /day dose: each had two treatment 
arms, one on a fixed dose of 10 mg /day and the other on 80 mg /day.   Assuming that atorvastatin 
10mg /day, fluvastatin 80mg /day, pravastatin 40mg /day and simvastatin 20/40mg /day provide 
similar benefits, the results can be used to represent the effectiveness achieved through standard 
statin treatment compared with no treatment. Excluded from this meta-analysis are more recent 
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placebo controlled trials with rosuvastatin 10 mg /day including the CORONA trial.{NEJM 
2007} 
 
The clinical benefit of intensive dose versus standard dose statin therapy is obtained from 
publications of event rates in four clinical trials14,12,13,11 and one previous economic evaluation.19 
The Pravastatin or Atorvastatin Evaluation and Infection Therapy14 study compared atorvastatin 
80 mg /day with pravastatin 40mg /day.  The Aggrastat to Zocor12 study compared simvastatin 
with a target dose of 80mg /day with simvastatin 20mg /day. The Treating to New Targets13  
study compared atorvastatin 80mg /day with atorvastatin 10mg /day.  The Incremental Decreases 
in End Points Through Aggressive Lipid Lowering11 study compared atorvastatin 80mg /day with 
simvastatin 20mg /day.  For the purpose of this analysis we assume that the intensive dose statin 
treatment arms are represented by atorvastatin 80mg /day and that the standard dose control arms 
are represented by simvastatin 20mg /day.20 
 
Due to differences in patients’ baseline characteristics the four statin head to head studies are 
categorised as: ACS trials;14,12 and stable CAD trials.13,11  Relative risks and corresponding 95% 
confidence intervals for hospitalization for unstable angina, non fatal MI, non fatal stroke, fatal 
coronary heart disease, and all cause mortality are estimated using random effects models.  These 
outcomes are chosen as they are reported in the majority of the four studies and most closely 
reflect the definitions used in the original meta-analysis of standard statin therapy and the health 
states in the existing model.  For the stable CAD studies, we assume that the combined fatal and 
non fatal stroke events can be used to represent rates for non fatal stroke.   
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Applying Relative Risks in the model 
The model is constructed with three distinct pathways: no treatment, standard dose statin and 
intensive dose statin.  Initial distribution across qualifying events and transitions to events in the 
no treatment arm are taken from the NICE statin model.15  Transitions to events in the standard 
dose arm are derived by applying the relative risk (RR) (Table 2) from the standard dose meta-
analyses to the no treatment arm transitions.15  Transitions to events in the intensive dose arm are 
derived by applying the RR (Table 2) from our meta-analyses to the standard dose transitions.  
The RR from the two ACS studies are applied to transitions from new event health states while 
the RR from the two stable CAD studies are applied to transitions from post event health states.  
This infers that the underlying disease for patients who do not have an event in the previous 12 
months stabilises somewhat.  This assumption is tested in univariate sensitivity analyses by 
varying the evidence source for the RRs applied during the first and subsequent years. 
 
Cost input parameters 
The cost of treatment and costs associated with the different health states modelled (Table 2) are 
obtained from a variety of UK specific sources (£ sterling, 2006).15  Statin treatment is costed 
annually assuming simvastatin 20mg /day for standard dose and atorvastatin 80mg/day for 
intensive dose, using prices listed in the British National Formulary.21  In the base case we 
assume 100% compliance for treatment costs as the RRs are estimated on an intention to treat 
basis.  
 
Costs for health states are based on the evidence used in the original statin economic evaluation.  
Costs for MI and fatal CHD are taken from the GP IIb/IIIa analysis by Palmer et al.22 Costs for 
stroke are taken from Chambers et al. weighted by the distribution of disabling and independent 
events.23  Follow on costs for post CHD event states are based on clinical input.   
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We assume no additional monitoring costs for the intensive dose treatment in the base case.  A 
sensitivity analysis is performed where costs are included to account for two additional GP visits 
and phlebotomy tests in the first year and one visit and test in subsequent years.  The model 
estimates costs from a UK NHS perspective as per recommendations hence only direct costs are 
included.24 In accordance with UK guidance, costs and benefits are discounted at 3.5% per 
annum.24   
     
INSERT TABLE 2: Relative risks, utilities and costs used in the model 
 
Utility input parameters 
The model assesses cost effectiveness in terms of the incremental cost per quality adjusted life 
year (QALY) gained.  Utility values are taken from UK based studies using the UK preference-
based weights for the EQ-5D where possible as advocated in the NICE reference case.24 It is 
assumed that patients in post event health states will incur an increase in quality of life in 
comparison to values modelled for the new event health states.  Quality of life is adjusted for age 
based on the UK general population estimates.25  All health state values are correlated for the 
probabilistic analyses and univariate sensitivity analyses are conducted to explore the impact of 
varying the individual parameters. 
 
Analyses 
The basecase is derived using 10,000 MonteCarlo simulations where the parameters are sampled 
simultaneously.   The impact of varying key parameters within their specified ranges is examined 
by holding the parameter value constant and sampling from all other parameters distributions 
simultaneously, again using 10,000 MonteCarlo simulations.  The variables include: health state 
costs (+/- 50%), treatment and monitoring costs, utility estimates, and the relative risks for the 
individual outcomes.  Results are also presented for different ages (50 and 70 years), and for 
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females.  In addition, the model is run using different RRs for fatal CHD and fatal stroke as 
opposed to the all cause mortality RR used in the basecase. 
 
RESULTS 
Average base case estimate 
The clinical and cost outcomes for a cohort of 1,000 patients are presented in Table 3.  During the 
first five years of treatment, standard dose statin therapy results in the avoidance of an average of 
71 vascular events (47 non fatal MIs, 9 non fatal strokes and 15 vascular deaths) compared with 
no treatment providing an average of 911 additional life years or 547 additional QALYs.  Over 
the full life time horizon, patients receiving standard dose statin treatment experience an average 
of 118 fewer vascular events that those receiving no treatment accruing an additional 547 
QALYs.  The cost offsets through events avoided (£404,478) are greater than the associated 
treatment costs (£328,848).  Standard dose statins are associated with greater health benefits and 
lower costs than no treatment.   
 
INSERT TABLE 3: Clinical outcomes and costs for a cohort of 1,000 males aged 60 years 
 
During the first five years of treatment, intensive dose statin therapy results in the avoidance of 
approximately 30 vascular events (14 non fatal MIs, 4 non fatal strokes and 11 vascular deaths) 
compared with standard dose treatment.   These provide an average additional 53 life years or 35 
QALYs.  Over the full life time horizon, patients receiving intensive dose statins are estimated to 
experience 71 fewer vascular events than those receiving standard dose statins.  Avoiding these 
events accrues an additional 276 life years or 172 QALYs.  With a total incremental cost of 
£4.1m, the cost per life year gained for intensive dose statin treatment compared with standard 
dose statin treatment is estimated to be £14,844 and the cost per QALY gained is estimated to be 
£23,779. 
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With a mean cost per QALY of £23,779 (Jackknife CI: £23,454 - £24,100), Figure 2 shows that 
for a decision threshold of £20,000 (£30,000) per QALY, intensive dose statin therapy is cost 
effective in approximately 43% (68%) of cases compared with standard dose therapy.  It should 
be noted that the CEAC never reaches one.  This tells us that on currently available evidence 
intensive dose statin may reduce the benefits compared with standard dose statin.   
 
INSERT FIGURE 2: Cost effectiveness acceptability curve for intensive dose versus standard 
dose statin treatment 
 
Deterministic sensitivity analyses 
The results of the deterministic sensitivity analyses undertaken to investigate the stability of the 
base case estimates are presented in Table 4.  When comparing standard dose statin therapy 
(simvastatin 20mg /day) with no treatment, the model is robust to variations in all the input 
parameters.  When comparing intensive dose with standard dose statin treatment, the model is 
robust to variations in a wide range of input parameters (Table 4 and Figure 3). The results 
demonstrate that treatment with intensive dose statin is a cost effective alternative for older aged 
cohorts.  The ICER decreases as the starting age increases (analysis 16) reflecting the greater 
potential for avoiding events associated with the higher baseline risk in the older age groups.  
 
INSERT TABLE 4: Results for one-way sensitivity analyses 
 
The key driver of cost effectiveness of intensive versus standard dose statins are the RRs applied 
for all cause mortality (range £11,034 (CI: £11,008; £11,060) per QALY to dominated).  If the 
RR for fatal CHD and fatal stroke are applied separately (analysis 8) as opposed to the all cause 
mortality RR the average ICER is estimated to be £19,474 (CI: £19,312; £19,637). Varying the 
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quality of life detriment associated with events by plus or minus 15% (analyses 10:11) produces 
ICERs ranging from £20,800 to £28,492. The results are not substantially affected when varying 
health state costs (analyses 2:4), costs associated with monitoring for intensive dose regimens 
(analysis 5), the relative risks for standard dose treatment (analyses 9:10) or changes in the 
relative risks for non fatal events for the intensive dose treatment (not shown). 
 
 
INSERT FIGURE 3: Tornado diagram showing robustness to changes in key parameters 
 
 
The price difference between the two therapies impacts on the cost effectiveness results. The base 
case assumes the standard dose is simvastatin 20mg /day at an annual cost of £24.25 per annum.  
If the cost for standard dose treatment is increased to £44.32 per annum (equivalent to simvastatin 
40mg /day), the ICER decreases to £22,657. However this does not taken into account any 
difference in efficacy between the two doses of simvastatin. The costs for atorvastatin 40mg /day 
and 80mg /day are currently equal at £367.74.  If it is assumed that this cost is reduced to £294.19 
per annum (analysis 6) the ICER reduces to £18,606.  
 
DISCUSSION 
 
We have shown that standard dose statins compared with no treatment for high risk patients with 
acute coronary syndrome are highly cost effective.  Treatment with intensive dose statin 
(represented by atorvastatin 80mg /day) offers additional benefits over standard dose (represented 
by simvastatin 20mg /day), but these additional benefits are smaller in magnitude than the 
benefits achieved when from moving from no statin to standard dose statins. In addition the cost 
offsets through avoided events when comparing intensive and standard dose statin regimens are 
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less than the associated treatment costs and result in a cost per QALY of around £24,000 for 
cohorts starting treatment at 60 years of age.    The incremental cost effectiveness ratio (ICER) 
decreases as the age of the cohort increases; for patients commencing treatment at the age of 70 
years the ICER is estimated to be around £14,000. This reflects the greater potential for avoiding 
events associated with the higher baseline risk in the older age groups and also the rise in the 
proportion of fatal to non-fatal events as age increases. If the price difference between 
atorvastatin and simvastatin diminishes significantly when generic atorvastatin becomes available 
in 2011,  this would undoubtedly make the case for intensive dose therapy more robust.                                                                                                                                          
 
The key drivers of cost effectiveness of intensive versus standard dose statins are the relative risk 
for mortality and, to a lesser extent, the cohort starting age and assumptions on utility. The results 
are particularly sensitive to uncertainty relating to the size of treatment effects on mortality in the 
first year. Previous meta-analyses have considered the impact of intensive dose statins on 
mortality. A meta-analysis of the four trials included within our analysis reported a trend toward 
decreasing cardiovascular mortality and, to a lesser extent, all-cause mortality but identified that it 
was underpowered to detect statistical differences with regard to these outcomes (Cannon et al 
2006).  A recent meta-analysis by Afilalo provides supporting evidence for the role of intensive 
dose statins in reducing mortality. The analysis concluded that in patients with recent ACS 
intensive statin therapy reduced all-cause mortality from 4.6% to 3.5% over 2.0 years (OR 0.75, 
95% CI 0.61 to 0.93).26 However, in patients with stable CHD, intensive statin therapy had no 
effect on all-cause mortality over 4.7 years (OR 0.99, 95% CI 0.89 to 1.11). In contrast MACE, 
defined as cardiovascular death or ACS or stroke, was comparably reduced in patients with recent 
ACS (OR 0.86, 95% CI 0.73 to 1.01) and stable CHD (OR 0.82, 95% CI 0.75 to 1.01).26 
 
The clinical evidence underlying the analysis is based on four trials which vary in terms of design 
and population studied. Two of the trials that used simvastatin 20mg /day as the standard statin 
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regimen (A to Z, IDEAL) showed no significant difference in their primary composite endpoints 
as compared to intensive statin regimens of simvastatin 80mg /day and atorvastatin 80mg /day.  
One of these was conducted in the context of ACS (A to Z) and the other in the context of CAD 
(IDEAL).  Conversely the two trials that used pravastatin 40mg /day and atorvastatin 10mg /day 
as the standard statin regimen (PROVE-IT & TNT) showed a significant difference in their 
primary composite endpoints as compared to intensive statin regimens of atorvastatin 80mg /day.  
Again, one of these was conducted in the acute context of ACS (PROVE-IT) and the other in the 
stable context of CAD (TNT).  This raises a question as to whether simvastatin 20mg /day might 
be a more effective standard statin regimen than pravastatin 40mg /day or atorvastatin 10mg /day.  
However, as each of these regimens achieved a similar mean LDL cholesterol of approximately 
100 mg/dl (2.6 mmol/L) during the conduct of these studies,26 the most likely explanation for this 
observation is the effects of chance and also other trial specific differences in individual trial 
design and conduct. 
 
Two published studies of the long term cost effectiveness of intensive dose statins have been 
identified.19,27 Chan et al considered the lifetime cost effectiveness of intensive-dose statin 
therapy in high risk patients aged 60 years with coronary artery disease. A Markov model was 
used, taking clinical effectiveness from the same four trials as our analysis. They concluded that 
intensive-dose statin is potentially highly cost-effective for patients aged 60 years with ACS, but 
less so for patients with CAD. Chan et al did not present results for different age groups.  In ACS 
the high dose strategy resulted in a gain of 0.35 QALYs per patient over a life time. The majority 
of these benefits accrued through the reduction in all cause mortality in the first two years of 
therapy. Our results suggest that few QALYs are gained, but this is due in part to the assumption 
that patients remain in the ACS state for one year rather than two. Even based on our more 
conservative assumptions the use of high dose statins remains cost effectiveness.  
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Lindgren et al evaluated the long term cost–effectiveness of intensive dose atorvastatin when 
compared with generic simvastatin for secondary prevention in four Scandinavian countries, 
based on the IDEAL trial.27 Both direct and indirect costs were included in the analysis. Cost 
effectiveness varied between 35 210 Euros (£26, 240 at £:EURO exchange rate of  1:1.341928) in 
Norway and 62 639 Euros (£46, 680 at £:Euro exchange rate of 1 : 1.1341928) in Finland, due to 
differences in price of the two drugs between countries. The price difference between the 
therapies was identified as one of the key drivers of the cost-effectiveness of high-dose 
atorvastatin. The inclusion of indirect costs makes it difficult to compare the results directly and 
given the potential uncertainties relating to the estimation of indirect costs29 it would be useful to 
be able to compare the results based on direct costs only.  
 
Our study has several limitations. The model does not include health states for hospital 
interventions (PCI, CABG) due to the absence of reliable data describing event rates in the UK. 
However the impact is likely to be small given that the cost of non-fatal MI in the first year, taken 
from Palmer et al, does include the cost of revascularisation for a proportion of patients.22  The 
stable CAD studies reported only combined fatal and non fatal stroke events and we assumed that 
these are representative of rates for non fatal stroke.  The model does not take into account the 
cost or utility impact of adverse events. Minor adverse events are likely to have limited resource 
and cost implications in terms of related medications and hospitalizations and therefore their 
omission is expected to have a limited impact on the ICER. Significant adverse events are rare, 
but are more likely with higher doses.30 Severe adverse events are assumed to lead to treatment 
discontinuation, exposing patients to placebo level of risks and are therefore taken into account by 
the intention-to–treat analysis. Patient adherence to treatment with statins is, however, a broader 
issue. It has been reported that only half the patients at highest risk after myocardial infarction 
continue to take their statins at 2 years,31 suggesting that not all the potential benefits for this 
group of patients are being realised.   
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Our base case analysis assumes that the relative risks derived from the two ACS studies are 
representative of the benefits in the first year after an event; the relative risks derived from the 
two CAD studies are assumed to be representative of the benefits in subsequent years. To test this 
assumption in sensitivity analysis the relative risks from the ACS studies were applied to all 
transitions. This increases the benefits over time and reduces the cost per QALY to £7,059.  
 
This analysis was undertaken using simvastatin 20mg /day as the standard dose statin, based on 
the available evidence with three of the four trials using simvastatin 20mg /day or pravastatin 
40mg /day as standard therapy. The use of simvastatin 40mg /day rather than 20mg /day would 
cost over 80%  more,  but produce only 6% more LDL cholesterol lowering and would therefore 
be expected to impact only slightly on  the benefits offered by intensive dose therapy.  However 
the clinical evidence is not currently available to assess the value of simvastatin 40mg /day 
following ACS and hence to directly compare these options. In addition, drug interactions for 
simvastatin 40 mg /day are likely to be a more significant issue. Screening data on 5,000 
contemporary UK ACS cases from the recent SPACE ROCKET trial  show that there are specific 
contraindications to simvastatin 40mg /day in 55% of patients due to interacting drug treatments; 
renal impairment; excess alcohol consumption / liver impairment or other general statin 
contraindication (Bailey et al. SPACE ROCKET screening registry - Personal Communication).   
 
In conclusion this analysis suggests that intensive statin regimens (represented by atorvastatin 
80mg /day) are cost effective compared with standard statin regimens (represented by simvastatin 
20mg /day) for patients with ACS over the age of 60 years. Recent registry studies report a mean 
age of 72 years for ACS patients admitted to UK hospitals32,33 and hence this comparison applies 
to the great majority of ACS patients.   Further research on the evidence of intensive dose statins 
on mortality for this patient group is required.  
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Table 1: Examples of transitions for patients receiving no treatment {Ward 2007} 
 
Markov model health state Non 
fatal 
MI 
Non 
fatal 
Stroke 
Fatal 
CHD 
Fatal 
Stroke 
Any 
event 
Age 55 years  
New UA (1st year after event) 4.97% - 5.55% 0.25% 10.77% 
Post UA (> 1st year after event) 3.48%  1.00% 0.04% 4.52% 
New MI (1st year after event) 11.52% 0.32% 3.19% 0.14% 15.18% 
Post MI (> 1st year after event) 1.79% 0.10% 0.91% 0.04% 2.84% 
New Stroke (1st year after event) 0.31% 4.59% 1.11% 1.11% 7.12% 
Post Stroke (> 1st year after event) 0.31% 1.86% 0.49% 0.49% 3.14% 
Age 65 years  
New UA (1st year after event) 4.88%  10.31% 0.46% 15.65% 
Post UA (> 1st year after event) 6.32%  1.19% 0.05% 7.57% 
New MI (1st year after event) 10.19% 0.68% 5.99% 0.27% 17.12% 
Post MI (> 1st year after event) 1.85% 0.22% 1.52% 0.07% 3.65% 
New Stroke (1st year after event) 0.55% 4.81% 2.60% 2.60% 10.56% 
Post Stroke (> 1st year after event) 0.55% 2.23% 1.04% 1.04% 4.87% 
Age 75 years  
New UA (1st year after event) 4.66%  16.71% 0.74% 22.11% 
Post UA (> 1st year after event) 11.22%  1.39% 0.06% 12.67% 
New MI (1st year after event) 8.74% 1.41% 10.88% 0.48% 21.51% 
Post MI (> 1st year after event) 1.78% 0.47% 2.35% 0.10% 4.71% 
New Stroke (1st year after event) 0.80% 4.83% 5.86% 5.86% 17.35% 
Post Stroke (> 1st year after event) 0.80% 2.46% 2.06% 2.06% 7.37% 
UA=unstable angina; MI=myocardial infarction, Str=stroke 
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Table 2: Relative risks, utilities and costs used in the model 
Parameter Mean Lower 
limit 
Upper limit Source (ref) 
RR: standard dose versus placebo 
non fatal MI  0.70 0.63 0.77 
non fatal Stroke 0.75 0.63 0.90 
fatal CHD 0.77 0.72 0.83 
fatal CVD (non CHD)    
all cause mortality 0.84 0.78 0.90 
{Ward 2007} 
RR ACS: intensive dose versus standard dose 
non fatal MI  0.92 0.78 1.07 
non fatal Stroke a 0.89 0.61 1.31 
fatal CHD 0.78 0.45 1.34 
fatal CVD (non CHD)    
all cause mortality 0.76 0.62 0.94 
{PROVE-IT  
A to Z} 
RR CAD: intensive dose versus standard dose 
non fatal MI  0.81 0.73 0.91 
non fatal Stroke a 0.82 0.70 0.96 
fatal CHD 0.90 0.73 1.11 
fatal CVD (non CHD)    
all cause mortality 0.99 0.89 1.10 
{TNT and 
IDEAL} 
Annual treatment costs 
Standard dose (20mg simvastatin) £24.25   
High dose (80mg atorvastatin) £367.74   
{BNF} 
Monitoring for intensive dose 
(yr1) 
£58.88   
Monitoring for intensive dose 
(yr2+) 
£29.44   
{PSSRU & 
Netten} 
Annual health state costsb 
New unstable angina £477 £358 £596 
Post unstable angina £201 £151 £251 
New MI £4,934 £3,701 £6,168 
Post MI £201 £151 £251 
Fatal CHD £1,261 £946 £1,576 
New stroke £8,070 £6,053 £10,088 
Post stroke £2,169 £1,627 £2,711 
Fatal stroke £7,425 £5,569 £9,281 
{Ward 2007} 
Utilities 
UA first year 0.77 0.65 0.89 {Ward 2007} 
UA subsequent year 0.72 0.85 0.97 assumed 
MI first year 0.65 0.76 0.87 {Ward 2007} 
MI subsequent year 0.71 0.84 0.96 assumed 
Stroke first year 0.53 0.63 0.72 {Ward 2007} 
Stroke subsequent year 0.59 0.69 0.80 assumed 
Age related utility    (Kind 1998) 
Constant 1.06 0.03   
Beta 0.00 0.00   
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a assumed same as “all stroke”. b inflated to 2006; RR=relative risk; MI=myocardial infarction; 
CHD=coronary heart disease; ACS=acute coronary syndrome; CAD=coronary artery disease; 
UA=unstable angina 
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Table 3: Clinical outcomes and costs: Average values for a cohort of 1,000 males aged 60 years 
(using 10,000 MonteCarlo simulations) 
 No 
treatment 
Standard 
dose statin 
High dose 
statin 
Clinical outcomes 
Initial 5 year period 
Number of MIs 154 107 93 
Number of Strokes 41 30 26 
Number of fatal CHD 90 75 65 
Number of fatal stroke 16 13 12 
Total number of events 300 225 195 
Discounted life years 3,759 3,827 3,880 
Discounted QALYs 2,387 2,434 2,469 
Lifetime model  
Number of MIs 323 258 222 
Number of Strokes 143 120 100 
Number of fatal CHD 363 340 327 
Number of fatal stroke 90 85 82 
Total number of events 920 802 731 
Discounted life years 11,130 12,041 12,317 
Discounted QALYs 6,815 7,362 7,534 
Cost outcomes (discounted) (£,000) 
Total costs (5 year) £3,691 £3,527 £4,787 
Total cost (lifetime) £10,617 £10,902 £15,000 
Cost effectiveness (lifetime horizon)  Standard vs 
No treatment 
High dose vs 
Standard 
Incremental life years  911 276 
Incremental QALYs  547 172 
Incremental costs  £285,617 £4,098,141 
Incremental cost per life year gained  £312 £14,844 
Incremental cost per QALY  £520 £23,779 
MI= myocardial infarction; CHD=coronary heart disease; DoC= death through other causes; 
QALY=quality adjusted life years. 
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Table 4: Results for deterministic sensitivity analyses (basecase: male age 60 years, lifetime 
horizon).  
  Standard versus  No treatment 
High dose versus  
Standard 
No. Analysis Cost QALY ICER Cost QALY ICER 
0 Base case £285 545 £520 £4,098 172 £23,779 
 Discount rates for costs and QALYs 
1 No discount £791 996 £794 £5,914 279 £21,169 
 Health State (HS) & monitoring costs  
2 HS costs: plus 50% £273 547 £498 £4,027 172 £23,429 
3 HS costs: minus 50% £286 547 £523 £4,162 169 £24,620 
4 Addition of monitoring cost for intensive dose £280 548 £510 £4,455 171 £26,086 
 Treatment costs       
5 
Increase cost of standard dose: to 
equivalent of simvastatin 
40mg=£44.32 pa 
£523 546 £958 £3,583 170 £22,657 
6 
Decrease cost of  intensive dose 
(to 80%): atorvastatin  80mg = 
£294.19 pa  
no change 
£3,192 172 £18,606 
 Health related quality of life  
6 HS utilities: plus 15% - lower detriment £279 629 £443 £4,092 197 £20,800 
7 HS utilities: minus 15% - higher detriment £279 465 £601 £4,091 144 £28,492 
 Effectiveness data  
8 
Separate RR for Fatal CHD and 
Fatal Stroke (with RR for non 
CVD death = 1) 
£157 507 £309 £4,165 214 £19,474 
 Using 95% CI for standard dose RR, holding intensive dose RR at mean values 
9 All Cause Mortality: LCI = 0.78 £564 751 £751 £4,193 165 £25,374 
10 All Cause Mortality: UCI = 0.90  £8.9 352 £25 £3,990 173 £23,129 
 Using 95% CI for CAD RR, holding standard dose and ACS RR at mean values 
11 All Cause Mortality: UCI =1.10 No change £3,590 -80 -£44,650 (Dd) 
12 All Cause Mortality: LCI =0.89 No change £4,587 416 £11,034 
 Using 95% CI for ACS RR, holding standard dose and CAD RR at mean values 
13 All Cause Mortality: UCI =0.94 No change £3,996 111 £36,089 
14 All Cause Mortality: LCI = 0.62 No change £4,212 243 £17,367 
  Cohort characteristics 
15 Male, starting age 50 years £238 526 £453 £5,196 137 £37,822 
16 Male, starting age 70 years £371 514 £721 £297 209 £14,205 
17 Female, starting age 60 years £538 537 £1,001 £4,411 174 £25,298 
 
ACS=acute coronary syndrome; RR=relative risk; CAD=coronary artery disease; UCI=upper 
confidence interval; LCI=lower confidence interval; MI=myocardial infarction; CHD = coronary 
heart disease. Pa = per annum 
Ds= Dominates - strategy is more effective and costs less 
Dd=Dominated - strategy is less effective and more expensive 
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Figure 1: Patient pathway in Markov Model 
 
 
 
 
The qualifying event includes 6 health states (new UA, new MI, new Stroke, post UA, post MI, 
post Stroke).  The absorbing health state, death, includes 3 health states (fatal CHD, fatal Stroke, 
death through other causes).  Transitions from new event health states use first year event rates 
while transitions from post event health states use subsequent year event rates.   
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Figure 2: Cost effectiveness acceptability curve for intensive dose versus standard dose statin 
treatment 
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Figure 3: Tornado diagram showing robustness to changes in key parameters   
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The variables that have the most influence on the cost per QALY estimated by the model have the 
widest bars at the top of the tornado diagram.  RR = relative risk; ACM = all cause mortality, 
ACS = acute coronary syndrome, CAD = coronary arterial disease HRQoL = health related 
quality of life; HS = health state. 
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